Effective Date:

Monday, November 06, 2023

Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, November 06, 2023

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Test Updates

Test	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
0450B	Aprobarbital, Blood								•
0450SP	Aprobarbital, Serum/Plasma								•
0450U	Aprobarbital, Urine								•
52253B	Carbinoxamine Confirmation, Blood		•	•	•			•	
52253FL	Carbinoxamine Confirmation, Fluid		•	•					
52253SP	Carbinoxamine Confirmation, Serum/Plasma		•	•	•			•	
52253TI	Carbinoxamine Confirmation, Tissue		•						
52253U	Carbinoxamine Confirmation, Urine		•	•	•				
0985B	Carbinoxamine, Blood		•	•	•			•	
52021B	Citalopram Confirmation, Blood							•	
52482B	Citalopram Confirmation, Blood							•	
52021FL	Citalopram Confirmation, Fluid							•	
52021SP	Citalopram Confirmation, Serum/Plasma							•	
52482SP	Citalopram Confirmation, Serum/Plasma							•	
52021TI	Citalopram Confirmation, Tissue							•	
52021U	Citalopram Confirmation, Urine							•	
52482U	Citalopram Confirmation, Urine							•	
1272B	Citalopram, Blood							•	
1272FL	Citalopram, Fluid							•	
1272SP	Citalopram, Serum/Plasma							•	
1272TI	Citalopram, Tissue							•	
1272U	Citalopram, Urine							•	
52510U	Cocaine and Metabolites DFC Confirmation, Urine	•							
52024B	Cyclizine and Metabolite Confirmation, Blood	•	•	•	•	•		•	
52024FL	Cyclizine and Metabolite Confirmation, Fluid	•	•	•		•			
52024SP	Cyclizine and Metabolite Confirmation, Serum/Plasma	•	•	•	•	•		•	
52024TI	Cyclizine and Metabolite Confirmation, Tissue	•	•	•		•			
52024U	Cyclizine and Metabolite Confirmation, Urine	•	•	•	•	•			
1390B	Cyclizine and Metabolite, Blood	•	•	•	•	•		•	
52026B	Cyproheptadine Confirmation, Blood		•	•	•				
52026FL	Cyproheptadine Confirmation, Fluid		•	•					

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Test Updates

Test	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52026SP	Cyproheptadine Confirmation, Serum/Plasma		•	•	•				
52026TI	Cyproheptadine Confirmation, Tissue		•	•					
52026U	Cyproheptadine Confirmation, Urine		•	•	•				
1425B	Cyproheptadine, Blood		•	•	•				
1425SP	Cyproheptadine, Serum/Plasma		•	•	•				
1425U	Cyproheptadine, Urine		•	•	•				
8075U	DUID/DRE Expanded Drug Screen Add-On, Urine (Forensic)			•	•				
1965B	Escitalopram, Blood							•	
1965FL	Escitalopram, Fluid							•	
10211P	Escitalopram, Plasma (CSA)							•	
10252P	Escitalopram, Plasma (CSA)							•	
1965SP	Escitalopram, Serum/Plasma							•	
1965U	Escitalopram, Urine							•	
52511U	Fluoxetine and Metabolite DFC Confirmation, Urine	•							
52512U	Ketamine and Metabolite DFC Confirmation, Urine	•							
52513U	Methadone and Metabolite DFC Confirmation, Urine	•							
8054B	NMS TotalTox™ Panel, Blood (Forensic)			•	•				
3250U	Oxalate, Urine								•
52094B	Oxybutynin and Metabolite Confirmation, Blood	•	•	•	•	•		•	
52094FL	Oxybutynin and Metabolite Confirmation, Fluid	•	•	•		•			
52094SP	Oxybutynin and Metabolite Confirmation, Serum/Plasma	•	•	•	•	•		•	
52094TI	Oxybutynin and Metabolite Confirmation, Tissue	•	•	•		•			
3266B	Oxybutynin and Metabolite, Blood	•	•	•	•	•		•	
3266SP	Oxybutynin and Metabolite, Serum/Plasma	•	•	•	•	•		•	
3266U	Oxybutynin and Metabolite, Urine	•	•	•	•	•		•	
8063B	Postmortem, Basic to Expanded Upgrade, Blood (Forensic)			•	•				
8063SP	Postmortem, Basic to Expanded Upgrade, Serum/Plasma (Forensic)			•	•				
8042B	Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood (Forensic)			•	•				

Test Updates

Test	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
10052B	Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)			•	•				
8057B	Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood - University of MI (Forensic) (CSA)			•	•				
8084B	Postmortem, Expanded w/Vitreous Alcohol and 6-MAM Confirmation, Blood (Forensic)			•	•				
8062B	Postmortem, Expanded w/o Alcohol, Blood (Forensic)			•	•				
8052B	Postmortem, Expanded, Blood (Forensic)			•	•				
90025B	Postmortem, Expanded, Blood (Forensic) (CSA)			•	•				
8052SP	Postmortem, Expanded, Serum/Plasma (Forensic)			•	•				
39052B	Postmortem, Expanded-II, Blood (Forensic) (SSA)			•	•				
39042B	Postmortem, Expanded-II, with Vitreous Alcohol Confirmation, Blood (Forensic) (SSA)			•	•				
10092B	Postmortem, Expert w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)			•	•				
10151B	Postmortem, Expert w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)			•	•				
5435B	Quinine/Quinidine Confirmation, Blood								•
9254B	Quinine/Quinidine Screen, Blood								•
52514U	Tramadol and Metabolite DFC Confirmation, Urine	•							
54345B	Trihexyphenidyl Confirmation (DUID/DRE), Blood		•	•	•				
54345U	Trihexyphenidyl Confirmation (Qualitative) (DUID/DRE), Urine		•	•	•				
52415B	Trihexyphenidyl Confirmation, Blood		•	•	•				
52415FL	Trihexyphenidyl Confirmation, Fluid		•	•					
52415SP	Trihexyphenidyl Confirmation, Serum/Plasma		•	•	•				
52415TI	Trihexyphenidyl Confirmation, Tissue		•	•					
52415U	Trihexyphenidyl Confirmation, Urine		•	•	•				
4680B	Trihexyphenidyl, Blood		•	•	•				
4680SP	Trihexyphenidyl, Serum/Plasma		•	•	•				
4680U	Trihexyphenidyl, Urine		•	•	•				
54188U	Triprolidine Confirmation (Qualitative) (DUID/DRE), Urine		•	•	•				
52297B	Triprolidine Confirmation, Blood		•	•	•				

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Test Updates

Test	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52297SP	Triprolidine Confirmation, Serum/Plasma		•	•	•				
52297U	Triprolidine Confirmation, Urine		•	•	•				
4720B	Triprolidine, Blood		•	•	•				
4720SP	Triprolidine, Serum/Plasma		•	•	•				
52135B	Xylazine Confirmation, Blood							•	
52135FL	Xylazine Confirmation, Fluid							•	
52135SP	Xylazine Confirmation, Serum/Plasma							•	
52135TI	Xylazine Confirmation, Tissue							•	
52135U	Xylazine Confirmation, Urine							•	
4815B	Xylazine, Blood							•	
4815SP	Xylazine, Serum/Plasma							•	
4815TI	Xylazine, Tissue							•	
4815U	Xylazine, Urine							•	

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Test Updates

Test Changes

52253B Carbinoxamine Confirmation, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Carbinoxamine

Analyte Name	Units	Reference Comment
Carbinoxamine	ng/mL	Following oral administration of 4 mg of carbinoxamine, a peak serum concentration of 8 ng/mL was reported at 2 hr that declined to 1.7 ng/mL by 12 hr. After oral administration of 8 mg of sustained-release carbinoxamine, a mean serum concentration after the 7th dose was reported as 37 ng/mL.

52253FL Carbinoxamine Confirmation, Fluid

Summary of Changes: Specimen Requirements were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Carbinoxamine

52253SP Carbinoxamine Confirmation, Serum/Plasma

Test Updates

Test Changes

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Carbinoxamine

Analyte Name	Units	Reference Comment
Carbinoxamine	ng/mL	Following oral administration of 4 mg of carbinoxamine, a peak serum concentration of 8 ng/mL was reported at 2 hr that declined to 1.7 ng/mL by 12 hr. After oral administration of 8 mg of sustained-release carbinoxamine, a mean serum concentration after the 7th dose was reported as 37 ng/mL.

52253TI Carbinoxamine Confirmation, Tissue

Summary of Changes:	Methods/CPT Codes were changed [LC-MS/MS (80375)]
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Carbinoxamine

52253U Carbinoxamine Confirmation, Urine

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Carbinoxamine

0985B Carbinoxamine, Blood

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Carbinoxamine

Analyte Name	Units	Reference Comment
Carbinoxamine	ng/mL	Following oral administration of 4 mg of carbinoxamine, a peak serum concentration of 8 ng/mL was reported at 2 hr that declined to 1.7 ng/mL by 12 hr. After oral administration of 8 mg of sustained-release carbinoxamine, a mean serum concentration after the 7th dose was reported as 37 ng/mL.

52021B Citalopram Confirmation, Blood

Summary of Changes:	Reference Comment was changed.

Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80332): Citalopram / Escitalopram
Method (CPT Code)

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	Steady-state serum or plasma levels from patients on a daily regimen of 30 to 60 mg Citalopram: 9-200 ng/mL. Steady-state peak plasma levels from patients on a regimen of 10 or 30 mg Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

52482B Citalopram Confirmation, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80332): Citalopram / Escitalopram
Method (CPT Code)

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	Steady-state serum or plasma levels from patients on a daily regimen of 30 to 60 mg Citalopram: 9-200 ng/mL. Steady-state peak plasma levels from patients on a regimen of 10 or 30 mg Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

52021FL Citalopram Confirmation, Fluid

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80332): Citalopram / Escitalopram
Method (CPT Code)

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

Test Updates

Test Changes

52021SP Citalopram Confirmation, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80332): Citalopram / Escitalopram
Method (CPT Code)

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	Steady-state serum or plasma levels from patients on a daily regimen of 30 to 60 mg Citalopram: 9-200 ng/mL. Steady-state peak plasma levels from patients on a regimen of 10 or 30 mg Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

52482SP Citalopram Confirmation, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80332): Citalopram / Escitalopram
Method (CPT Code)

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	Steady-state serum or plasma levels from patients on a daily regimen of 30 to 60 mg Citalopram: 9-200 ng/mL. Steady-state peak plasma levels from patients on a regimen of 10 or 30 mg Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

52021TI Citalopram Confirmation, Tissue

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80332): Citalopram / Escitalopram
Method (CPT Code)

Test Updates

Test Changes

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/g	This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

52021U Citalopram Confirmation, Urine

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80332): Citalopram / Escitalopram
Method (CPT Code)

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	For Citalopram, approximately 32% of an oral dose is eliminated in urine as unchanged drug following chronic daily administration. For Escitalopram, approximately 8% of a dose is eliminated in urine as unchanged drug. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

52482U Citalopram Confirmation, Urine

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80332): Citalopram / Escitalopram
Method (CPT Code)

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	For Citalopram, approximately 32% of an oral dose is eliminated in urine as unchanged drug following chronic daily administration. For Escitalopram, approximately 8% of a dose is eliminated in urine as unchanged drug. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

1272B Citalopram, Blood

Summary of Changes: Reference Comment was changed.

Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80332): Citalopram / Escitalopram
Method (CPT Code)

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	Steady-state serum or plasma levels from patients on a daily regimen of 30 to 60 mg Citalopram: 9-200 ng/mL. Steady-state peak plasma levels from patients on a regimen of 10 or 30 mg Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

1272FL Citalopram, Fluid

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80332): Citalopram / Escitalopram
Method (CPT Code)

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

1272SP Citalopram, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80332): Citalopram / Escitalopram
Method (CPT Code)

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	Steady-state serum or plasma levels from patients on a daily regimen of 30 to 60 mg Citalopram: 9-200 ng/mL. Steady-state peak plasma levels from patients on a regimen of 10 or 30 mg Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

Test Updates

Test Changes

1272TI Citalopram, Tissue

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80332): Citalopram / Escitalopram

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/g	This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

1272U Citalopram, Urine

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80332): Citalopram / Escitalopram

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	For Citalopram, approximately 32% of an oral dose is eliminated in urine as unchanged drug following chronic daily administration. For Escitalopram, approximately 8% of a dose is eliminated in urine as unchanged drug. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

52510U Cocaine and Metabolites DFC Confirmation, Urine

Summary of Changes: Test Name was changed.

52024B Cyclizine and Metabolite Confirmation, Blood

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Norcyclizine was added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Cyclizine, Norcyclizine

Analyte Name	Units	Reference Comment
Cyclizine	ng/mL	Following a single oral dose of 50 mg, a peak blood concentration for 69 ng/mL has been reported at two hours. Oral doses of 50 mg given three times a day for 5 days to elderly patients resulted in a reported mean steady state cyclizine plasma concentration of 109 ng/mL (range, 20-574).
Norcyclizine	ng/mL	Oral doses of 50 mg TID cyclizine given to 12 palliative care patients led to an average norcyclizine steady-state plasma concentration of 51 ng/mL (range: 10-260 ng/mL). Ten of these patients received a 150 mg/24 hr continuous subcutaneous infusion developed a median norcyclizine steady-state plasma concentration of 16 ng/mL (range: 5-27 ng/mL).

52024FL Cyclizine and Metabolite Confirmation, Fluid

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Scope of Analysis was changed. Norcyclizine was added. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	2 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Cyclizine, Norcyclizine

Test Updates

Test Changes

Analyte Name	Units	Reference Comment
Norcyclizine	ng/mL	Norcyclizine is a cyclizine metabolite.

52024SP Cyclizine and Metabolite Confirmation, Serum/Plasma

Summary of Changes:
Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Norcyclizine was added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80375): Cyclizine, Norcyclizine
Method (CPT Code)

Analyte Name	Units	Reference Comment
Cyclizine	ng/mL	Following a single oral dose of 50 mg, a peak blood concentration for 69 ng/mL has been reported at two hours. Oral doses of 50 mg given three times a day for 5 days to elderly patients resulted in a reported mean steady state cyclizine plasma concentration of 109 ng/mL (range, 20-574).
Norcyclizine	ng/mL	Oral doses of 50 mg TID cyclizine given to 12 palliative care patients led to an average norcyclizine steady-state plasma concentration of 51 ng/mL (range: 10-260 ng/mL). Ten of these patients received a 150 mg/24 hr continuous subcutaneous infusion developed a median norcyclizine steady-state plasma concentration of 16 ng/mL (range: 5-27 ng/mL).

52024TI Cyclizine and Metabolite Confirmation, Tissue

Test Changes

Summary of Changes: Test Name was changed.
Specimen Requirements (Specimen Container) were changed.
Scope of Analysis was changed.
Norcyclizine was added.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 10 g Tissue
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code) LC-MS/MS (80375): Cyclizine, Norcyclizine

Analyte Name	Units	Reference Comment
Norcyclizine	ng/g	Norcyclizine is a cyclizine metabolite.

52024U Cyclizine and Metabolite Confirmation, Urine

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Stability was changed.
Scope of Analysis was changed.
Norcyclizine was added.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (80375): Cyclizine, Norcyclizine

Analyte Name	Units	Reference Comment
Norcyclizine	ng/mL	Norcyclizine is a cyclizine metabolite.

1390B Cyclizine and Metabolite, Blood

Test Updates

Test Changes

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Scope of Analysis was changed. Norcyclizine was added. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Cyclizine, Norcyclizine

Analyte Name	Units	Reference Comment
Cyclizine	ng/mL	Following a single oral dose of 50 mg, a peak blood concentration for 69 ng/mL has been reported at two hours. Oral doses of 50 mg given three times a day for 5 days to elderly patients resulted in a reported mean steady state cyclizine plasma concentration of 109 ng/mL (range, 20-574).
Norcyclizine	ng/mL	Oral doses of 50 mg TID cyclizine given to 12 palliative care patients led to an average norcyclizine steady-state plasma concentration of 51 ng/mL (range: 10-260 ng/mL). Ten of these patients received a 150 mg/24 hr continuous subcutaneous infusion developed a median norcyclizine steady-state plasma concentration of 16 ng/mL (range: 5-27 ng/mL).

52026B Cyproheptadine Confirmation, Blood

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Cyproheptadine

52026FL Cyproheptadine Confirmation, Fluid

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	2 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Cyproheptadine

52026SP Cyproheptadine Confirmation, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

Test Updates

Test Changes

Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Cyproheptadine

52026TI Cyproheptadine Confirmation, Tissue

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 10 g Tissue
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Cyproheptadine

52026U Cyproheptadine Confirmation, Urine

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 1 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Cyproheptadine

1425B Cyproheptadine, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Cyproheptadine

1425SP Cyproheptadine, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Cyproheptadine

1425U Cyproheptadine, Urine

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Test Updates

Test Changes

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 1 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Cyproheptadine

8075U DUID/DRE Expanded Drug Screen Add-On, Urine (Forensic)

Summary of Changes:	Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed.

Specimen Requirements:	6 mL Urine
Transport Temperature:	Frozen
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 14 day(s) If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory. NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

1965B Escitalopram, Blood

Summary of Changes:	Reference Comment was changed.

Scope of Analysis: Method (CPT Code)	LC-MS/MS (80332): Citalopram / Escitalopram

Test Updates

Test Changes

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	Steady-state serum or plasma levels from patients on a daily regimen of 30 to 60 mg Citalopram: 9-200 ng/mL. Steady-state peak plasma levels from patients on a regimen of 10 or 30 mg Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

1965FL Escitalopram, Fluid

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80332): Citalopram / Escitalopram

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

10211P Escitalopram, Plasma (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80332): Citalopram / Escitalopram

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	Steady-state peak plasma levels from patients on regimen of 10 or 30 mg/day of Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

10252P Escitalopram, Plasma (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80332): Citalopram / Escitalopram

Test Updates

Test Changes

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	Steady-state peak plasma levels from patients on regimen of 10 or 30 mg/day of Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

1965SP Escitalopram, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80332): Citalopram / Escitalopram

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	Steady-state serum or plasma levels from patients on a daily regimen of 30 to 60 mg Citalopram: 9-200 ng/mL. Steady-state peak plasma levels from patients on a regimen of 10 or 30 mg Escitalopram: 21 and 64 ng/mL, respectively, and occur at approximately 4 hours post dose. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

1965U Escitalopram, Urine

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80332): Citalopram / Escitalopram

Analyte Name	Units	Reference Comment
Citalopram / Escitalopram	ng/mL	For Citalopram, approximately 32% of an oral dose is eliminated in urine as unchanged drug following chronic daily administration. For Escitalopram, approximately 8% of a dose is eliminated in urine as unchanged drug. This test is not chiral specific; therefore, Citalopram and/or Escitalopram may be present. Concentrations are dependent on the form of drug administered.

Test Updates

Test Changes

52511U Fluoxetine and Metabolite DFC Confirmation, Urine

Summary of Changes: Test Name was changed.

52512U Ketamine and Metabolite DFC Confirmation, Urine

Summary of Changes: Test Name was changed.

52513U Methadone and Metabolite DFC Confirmation, Urine

Summary of Changes: Test Name was changed.

8054B NMS TotalTox™ Panel, Blood (Forensic)

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements:	10 mL Blood
Transport Temperature:	Frozen
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature. Received Refrigerated. Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 7 day(s) If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory. NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

52094B Oxybutynin and Metabolite Confirmation, Blood

Test Updates

Test Changes

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Desethyl Oxybutynin was added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (80375): Oxybutynin, Desethyl Oxybutynin

Analyte Name	Units	Reference Comment
Oxybutynin	ng/mL	Following 5 mg oral doses of immediate release oxybutynin given three times a day for 2 weeks resulted in a reported mean peak plasma oxybutynin concentration of 18 ng/mL. Once daily oral administration of 5 mg extended release oxybutynin for 4 days yielded a reported average peak plasma oxybutynin value of 6.7 ng/mL.
Desethyl Oxybutynin	ng/mL	Desethyl oxybutynin is a pharmacologically active oxybutynin metabolite. A 36 mg transdermal patch applied to the hip of 24 healthy adults produced average peak desethyl oxybutynin plasma concentrations of 5.7 ng/mL at 48 hours post application. Oral doses of 5 mg oxybutynin TID given to elderly women for 2 weeks led to an average peak desethyl oxybutynin concentration of 63 ng/mL at 1.1 hours after the last dose. Once daily administration of 5 mg extended release tablets for four days given to healthy older women produced average peak plasma concentrations of 23 ng/mL.

52094FL Oxybutynin and Metabolite Confirmation, Fluid

Test Updates

Test Changes

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Scope of Analysis was changed. Desethyl Oxybutynin was added. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	2 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Oxybutynin, Desethyl Oxybutynin

Analyte Name	Units	Reference Comment
Desethyl Oxybutynin	ng/mL	Desethyl oxybutynin is a pharmacologically active oxybutynin metabolite.

52094SP Oxybutynin and Metabolite Confirmation, Serum/Plasma

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Scope of Analysis was changed. Desethyl Oxybutynin was added. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Oxybutynin, Desethyl Oxybutynin

Test Updates

Test Changes

Analyte Name	Units	Reference Comment
Oxybutynin	ng/mL	Following 5 mg oral doses of immediate release oxybutynin given three times a day for 2 weeks resulted in a reported mean peak plasma oxybutynin concentration of 18 ng/mL. Once daily oral administration of 5 mg extended release oxybutynin for 4 days yielded a reported average peak plasma oxybutynin value of 6.7 ng/mL.
Desethyl Oxybutynin	ng/mL	Desethyl oxybutynin is a pharmacologically active oxybutynin metabolite. A 36 mg transdermal patch applied to the hip of 24 healthy adults produced average peak desethyl oxybutynin plasma concentrations of 5.7 ng/mL at 48 hours post application. Oral doses of 5 mg oxybutynin TID given to elderly women for 2 weeks led to an average peak desethyl oxybutynin concentration of 63 ng/mL at 1.1 hours after the last dose. Once daily administration of 5 mg extended release tablets for four days given to healthy older women produced average peak plasma concentrations of 23 ng/mL.

52094TI Oxybutynin and Metabolite Confirmation, Tissue

Summary of Changes:	Test Name was changed. Specimen Requirements (Specimen Container) were changed. Scope of Analysis was changed. Desethyl Oxybutynin was added. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	10 g Tissue
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Oxybutynin, Desethyl Oxybutynin

Analyte Name	Units	Reference Comment
Desethyl Oxybutynin	ng/g	Desethyl oxybutynin is a pharmacologically active oxybutynin metabolite.

Test Updates

Test Changes

3266B Oxybutynin and Metabolite, Blood

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
Desethyl Oxybutynin was added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 5 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (80375): Oxybutynin, Desethyl Oxybutynin

Analyte Name	Units	Reference Comment
Oxybutynin	ng/mL	Following 5 mg oral doses of immediate release oxybutynin given three times a day for 2 weeks resulted in a reported mean peak plasma oxybutynin concentration of 18 ng/mL. Once daily oral administration of 5 mg extended release oxybutynin for 4 days yielded a reported average peak plasma oxybutynin value of 6.7 ng/mL.
Desethyl Oxybutynin	ng/mL	Desethyl oxybutynin is a pharmacologically active oxybutynin metabolite. A 36 mg transdermal patch applied to the hip of 24 healthy adults produced average peak desethyl oxybutynin plasma concentrations of 5.7 ng/mL at 48 hours post application. Oral doses of 5 mg oxybutynin TID given to elderly women for 2 weeks led to an average peak desethyl oxybutynin concentration of 63 ng/mL at 1.1 hours after the last dose. Once daily administration of 5 mg extended release tablets for four days given to healthy older women produced average peak plasma concentrations of 23 ng/mL.

Test Updates

Test Changes

3266SP Oxybutynin and Metabolite, Serum/Plasma

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Scope of Analysis was changed. Desethyl Oxybutynin was added. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Oxybutynin, Desethyl Oxybutynin

Analyte Name	Units	Reference Comment
Oxybutynin	ng/mL	Following 5 mg oral doses of immediate release oxybutynin given three times a day for 2 weeks resulted in a reported mean peak plasma oxybutynin concentration of 18 ng/mL. Once daily oral administration of 5 mg extended release oxybutynin for 4 days yielded a reported average peak plasma oxybutynin value of 6.7 ng/mL.
Desethyl Oxybutynin	ng/mL	Desethyl oxybutynin is a pharmacologically active oxybutynin metabolite. A 36 mg transdermal patch applied to the hip of 24 healthy adults produced average peak desethyl oxybutynin plasma concentrations of 5.7 ng/mL at 48 hours post application. Oral doses of 5 mg oxybutynin TID given to elderly women for 2 weeks led to an average peak desethyl oxybutynin concentration of 63 ng/mL at 1.1 hours after the last dose. Once daily administration of 5 mg extended release tablets for four days given to healthy older women produced average peak plasma concentrations of 23 ng/mL.

Test Updates

Test Changes

3266U Oxybutynin and Metabolite, Urine

Summary of Changes:	Test Name was changed. Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Scope of Analysis was changed. Desethyl Oxybutynin was added. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 1 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Oxybutynin, Desethyl Oxybutynin

Analyte Name	Units	Reference Comment
Oxybutynin	ng/mL	[Reference comment removed]
Desethyl Oxybutynin	ng/mL	Desethyl oxybutynin is an oxybutynin metabolite.

8063B Postmortem, Basic to Expanded Upgrade, Blood (Forensic)

Summary of Changes:	Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed.

Specimen Requirements:	10 mL Blood
Transport Temperature:	Frozen
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Peak sample should be drawn 60 minutes after an intramuscular injection, 30 minutes after the end of a 30 minute intravenous infusion. Trough sample should be drawn immediately prior to next dose. Promptly centrifuge and separate Serum into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Received Refrigerated.

Test Updates

Test Changes

Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 7 day(s)

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.
NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

8063SP Postmortem, Basic to Expanded Upgrade, Serum/Plasma (Forensic)

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 10 mL Serum or Plasma

Transport Temperature: Frozen

Specimen Container: Lavender top tube (EDTA), Plastic container (preservative-free), Red top tube (no additive)

Light Protection: Not Required

Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Peak serum levels are recommended when monitoring patients because the level in the blood drops so rapidly that many negative results are found at the trough. The peak occurs at 40 to 90 minutes post dose. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Sample should be collected 1 to 6 hours post dose. Glass containers are not acceptable.

Rejection Criteria: Received Room Temperature. Received Refrigerated. Polymer gel separation tube (PST). Polymer gel separation tube (SST or PST).

Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 14 day(s)

Duloxetine in Serum/Plasma requires light protection when submitted at Room Temperature.

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.
NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

10052B Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)

Test Updates

Test Changes

Summary of Changes:	Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed.

Specimen Requirements:	10 mL Blood
Transport Temperature:	Frozen
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	In addition to blood, collect 1 mL of Vitreous fluid for the Alcohol Confirmation. Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 7 day(s) If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory. NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

8042B Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood (Forensic)

Summary of Changes:	Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed.

Specimen Requirements:	10 mL Blood
Transport Temperature:	Frozen
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	In addition to blood, collect 1 mL of Vitreous fluid for the Alcohol Confirmation. Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature. Received Refrigerated.

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Test Updates

Test Changes

Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 7 day(s)

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.
NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

8057B Postmortem, Expanded w/Vitreous Alcohol Confirmation, Blood - University of MI (Forensic) (CSA)

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 10 mL Blood
Transport Temperature: Frozen
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 7 day(s)

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.
NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

8084B Postmortem, Expanded w/Vitreous Alcohol and 6-MAM Confirmation, Blood (Forensic)

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Test Updates

Test Changes

Specimen Requirements:	10 mL Blood
Transport Temperature:	Frozen
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 7 day(s) If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory. NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

8062B Postmortem, Expanded w/o Alcohol, Blood (Forensic)

Summary of Changes:	Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed.

Specimen Requirements:	10 mL Blood
Transport Temperature:	Frozen
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Submit with Chain of Custody. Ensure that container remains tightly sealed.
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 7 day(s) If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory. NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

90025B Postmortem, Expanded, Blood (Forensic) (CSA)

Test Updates

Test Changes

Summary of Changes:	Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed.

Specimen Requirements:	10 mL Blood
Transport Temperature:	Frozen
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 7 day(s) If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory. NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

8052B Postmortem, Expanded, Blood (Forensic)

Summary of Changes:	Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed.

Specimen Requirements:	10 mL Blood
Transport Temperature:	Frozen
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 7 day(s) If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory. NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

Test Updates

Test Changes

8052SP Postmortem, Expanded, Serum/Plasma (Forensic)

Summary of Changes:	Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed.

Specimen Requirements:	10 mL Serum or Plasma
Transport Temperature:	Frozen
Specimen Container:	Lavender top tube (EDTA), Plastic container (preservative-free), Red top tube (no additive)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate). Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Received Room Temperature. Received Refrigerated. Polymer gel separation tube (PST). Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 14 day(s) Duloxetine in Serum/Plasma requires light protection when submitted at Room Temperature. If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory. NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

39052B Postmortem, Expanded-II, Blood (Forensic) (SSA)

Summary of Changes:	Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed.

Specimen Requirements:	10 mL Blood
Transport Temperature:	Frozen
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature. Received Refrigerated.

Test Updates

Test Changes

Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 7 day(s)

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.
NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

39042B Postmortem, Expanded-II, with Vitreous Alcohol Confirmation, Blood (Forensic) (SSA)

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 10 mL Blood
Transport Temperature: Frozen
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: Collect sample using alcohol free skin preparation.
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 7 day(s)

If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory.
NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

10092B Postmortem, Expert w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Test Updates

Test Changes

Specimen Requirements:	10 mL Blood
Transport Temperature:	Frozen
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	In addition to blood, collect 1 mL of Vitreous fluid for the Alcohol Confirmation. Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature. Received Refrigerated. Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 7 day(s) If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory. NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

10151B Postmortem, Expert w/Vitreous Alcohol Confirmation, Blood (Forensic) (CSA)

Summary of Changes:	Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed.

Specimen Requirements:	10 mL Blood
Transport Temperature:	Frozen
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate), Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Collect sample using alcohol free skin preparation.
Rejection Criteria:	Received Room Temperature. Received Refrigerated. Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 7 day(s) If this test contains multiple compounds, the reported stability reflects that which is least stable. Stability may vary among compounds included in the test and may be dependent upon matrix, pH, collection tube, and storage temperature. Negative results should be interpreted with caution. For more information on stability of a specific compound please contact the laboratory. NOTE: If the test contains multiple compounds samples received at room temperature will not be rejected.

52514U Tramadol and Metabolite DFC Confirmation, Urine

Test Updates

Test Changes

Summary of Changes: Test Name was changed.

54345B Trihexyphenidyl Confirmation (DUID/DRE), Blood

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 12 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Trihexyphenidyl

54345U Trihexyphenidyl Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Urine
Transport Temperature:	Frozen
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Stability:	Room Temperature: 1 day(s) Refrigerated: 1 day(s) Frozen (-20 °C): 12 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Trihexyphenidyl

52415B Trihexyphenidyl Confirmation, Blood

Test Updates

Test Changes

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 12 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Trihexyphenidyl

52415FL Trihexyphenidyl Confirmation, Fluid

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	2 mL Fluid
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Trihexyphenidyl

52415SP Trihexyphenidyl Confirmation, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Test Updates

Test Changes

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 12 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Trihexyphenidyl

52415TI Trihexyphenidyl Confirmation, Tissue

Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	10 g Tissue
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Trihexyphenidyl

52415U Trihexyphenidyl Confirmation, Urine

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Urine
Transport Temperature:	Frozen
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature. Received Refrigerated.

Test Updates

Test Changes

Stability:	Room Temperature: 1 day(s) Refrigerated: 1 day(s) Frozen (-20 °C): 12 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Trihexyphenidyl

4680B Trihexyphenidyl, Blood

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 12 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Trihexyphenidyl

4680SP Trihexyphenidyl, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 12 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Trihexyphenidyl

4680U Trihexyphenidyl, Urine

Test Updates

Test Changes

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Transport Temperature) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Urine
Transport Temperature:	Frozen
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature. Received Refrigerated.
Stability:	Room Temperature: 1 day(s) Refrigerated: 1 day(s) Frozen (-20 °C): 12 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Trihexyphenidyl

54188U Triprolidine Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Triprolidine

52297B Triprolidine Confirmation, Blood

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Test Updates

Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Triprolidine

52297SP Triprolidine Confirmation, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Triprolidine

52297U Triprolidine Confirmation, Urine

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Test Updates

Test Changes

Specimen Requirements:	1 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Triprolidine

4720B Triprolidine, Blood

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80375): Triprolidine

4720SP Triprolidine, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).

Test Updates

Test Changes

Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)

Scope of Analysis: LC-MS/MS (80375): Triprolidine
Method (CPT Code)

52135B Xylazine Confirmation, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80375): Xylazine
Method (CPT Code)

Analyte Name	Units	Reference Comment
Xylazine	ng/mL	Xylazine is a veterinary sedative, analgesic, and anesthetic in large animals (e.g., cattle) that is also found as an adulterant in illicit drugs such as fentanyl. It is not approved for human use. Blood concentrations in approximately 3000 postmortem cases and 130 driving under the influence of drugs cases were 5.0-1700 ng/mL (Mean: 34 +/- 1 ng/mL) and 5.1-450 ng/mL (Mean: 36 +/- 4 ng/mL), respectively; 99% of cases contained an opioid, primarily fentanyl. Two postmortem cases with xylazine concentrations of 9100 and 11000 ng/mL were determined to be intentional xylazine overdoses. Serum/plasma concentrations in non-fatal exposures were 30-1500 ng/mL. The blood to serum/plasma ratio of xylazine is unknown.

52135FL Xylazine Confirmation, Fluid

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80375): Xylazine
Method (CPT Code)

Analyte Name	Units	Reference Comment
Xylazine	ng/mL	Xylazine is a veterinary sedative, analgesic, and anesthetic in large animals (e.g., cattle) that is also found as an adulterant in illicit drugs such as fentanyl. It is not approved for human use.

52135SP Xylazine Confirmation, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80375): Xylazine
Method (CPT Code)

Analyte Name	Units	Reference Comment
Xylazine	ng/mL	Xylazine is a veterinary sedative, analgesic, and anesthetic in large animals (e.g., cattle) that is also found as an adulterant in illicit drugs such as fentanyl. It is not approved for human use. Blood concentrations in approximately 3000 postmortem cases and 130 driving under the influence of drugs cases were 5.0-1700 ng/mL (Mean: 34 +/- 1 ng/mL) and 5.1-450 ng/mL (Mean: 36 +/- 4 ng/mL), respectively; 99% of cases contained an opioid, primarily fentanyl. Two postmortem cases with xylazine concentrations of 9100 and 11000 ng/mL were determined to be intentional xylazine overdoses. Serum/plasma concentrations in non-fatal exposures were 30-1500 ng/mL. The blood to serum/plasma ratio of xylazine is unknown.

52135TI Xylazine Confirmation, Tissue

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80375): Xylazine
Method (CPT Code)

Analyte Name	Units	Reference Comment
Xylazine	ng/g	Xylazine is a veterinary sedative, analgesic, and anesthetic in large animals (e.g., cattle) that is also found as an adulterant in illicit drugs such as fentanyl. It is not approved for human use.

52135U Xylazine Confirmation, Urine

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80375): Xylazine
Method (CPT Code)

Analyte Name	Units	Reference Comment
Xylazine	ng/mL	Xylazine is a veterinary sedative, analgesic, and anesthetic in large animals (e.g., cattle) that is also found as an adulterant in illicit drugs such as fentanyl. It is not approved for human use.

4815B Xylazine, Blood

Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80375): Xylazine
Method (CPT Code)

Analyte Name	Units	Reference Comment
Xylazine	ng/mL	Xylazine is a veterinary sedative, analgesic, and anesthetic in large animals (e.g., cattle) that is also found as an adulterant in illicit drugs such as fentanyl. It is not approved for human use. Blood concentrations in approximately 3000 postmortem cases and 130 driving under the influence of drugs cases were 5.0-1700 ng/mL (Mean: 34 +/- 1 ng/mL) and 5.1-450 ng/mL (Mean: 36 +/- 4 ng/mL), respectively; 99% of cases contained an opioid, primarily fentanyl. Two postmortem cases with xylazine concentrations of 9100 and 11000 ng/mL were determined to be intentional xylazine overdoses. Serum/plasma concentrations in non-fatal exposures were 30-1500 ng/mL. The blood to serum/plasma ratio of xylazine is unknown.

4815SP Xylazine, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80375): Xylazine
Method (CPT Code)

Analyte Name	Units	Reference Comment
Xylazine	ng/mL	Xylazine is a veterinary sedative, analgesic, and anesthetic in large animals (e.g., cattle) that is also found as an adulterant in illicit drugs such as fentanyl. It is not approved for human use. Blood concentrations in approximately 3000 postmortem cases and 130 driving under the influence of drugs cases were 5.0-1700 ng/mL (Mean: 34 +/- 1 ng/mL) and 5.1-450 ng/mL (Mean: 36 +/- 4 ng/mL), respectively; 99% of cases contained an opioid, primarily fentanyl. Two postmortem cases with xylazine concentrations of 9100 and 11000 ng/mL were determined to be intentional xylazine overdoses. Serum/plasma concentrations in non-fatal exposures were 30-1500 ng/mL. The blood to serum/plasma ratio of xylazine is unknown.

Effective Date:

Monday, November 06, 2023

Test Updates

Test Changes

4815TI Xylazine, Tissue

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Xylazine

Analyte Name	Units	Reference Comment
Xylazine	ng/g	Xylazine is a veterinary sedative, analgesic, and anesthetic in large animals (e.g., cattle) that is also found as an adulterant in illicit drugs such as fentanyl. It is not approved for human use.

4815U Xylazine, Urine

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Xylazine

Analyte Name	Units	Reference Comment
Xylazine	ng/mL	Xylazine is a veterinary sedative, analgesic, and anesthetic in large animals (e.g., cattle) that is also found as an adulterant in illicit drugs such as fentanyl. It is not approved for human use.

Test Updates

Discontinued Tests

Test	Test Name	Alternative Test
0450B	Aprobarbital, Blood	No Alternate Tests Available
0450SP	Aprobarbital, Serum/Plasma	No Alternate Tests Available
0450U	Aprobarbital, Urine	No Alternate Tests Available
3250U	Oxalate, Urine	No Alternate Tests Available
5435B	Quinine/Quinidine Confirmation, Blood	No Alternate Tests Available
9254B	Quinine/Quinidine Screen, Blood	4075B - Quinine/Quinidine Differentiation, Blood

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com